Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Total revenues	$ 12,319	$ 13,538	$ 27,901	$ 27,580
Cost of product revenue	2,772	2,611	7,163	6,436
Research and development	8,274	7,370	16,290	14,548
Selling, general and administrative	7,896	7,395	16,311	15,141
Total costs and operating expenses	18,942	17,376	39,764	36,125
Loss from operations	(6,623)	(3,838)	(11,863)	(8,545)
Depreciation and amortization			(693)	(503)
Loss before income taxes	(6,491)	(3,746)	(11,624)	(8,442)
Stock-based compensation	1,988	2,457	4,051	4,437
Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	10,589	11,165	20,676	21,894
Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	1,730	2,373	7,225	5,686
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	12,319	13,538	27,901	27,580
Cost of product revenue	2,772	2,611	7,163	6,436
Research and development	7,990	7,166	15,748	14,164
Selling, general and administrative	2,923	2,033	5,541	4,275
Total costs and operating expenses	13,685	11,810	28,452	24,875
Loss from operations	(1,366)	1,728	(551)	2,705
Stock-based compensation	798	851	1,575	1,472
Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	10,589	11,165	20,676	21,894
Cost of product revenue	2,772	2,611	7,163	6,436
Research and development	5,134	4,724	9,576	9,790
Selling, general and administrative	2,362	1,729	4,463	3,825
Total costs and operating expenses	10,268	9,064	21,202	20,051
Loss from operations	321	2,101	(526)	1,843
Stock-based compensation	601	768	1,237	1,326
Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	1,730	2,373	7,225	5,686
Cost of product revenue	0	0	0	0
Research and development	2,856	2,442	6,172	4,374
Selling, general and administrative	561	304	1,078	450
Total costs and operating expenses	3,417	2,746	7,250	4,824
Loss from operations	(1,687)	(373)	(25)	862
Stock-based compensation	197	83	338	146
Corporate [Member]
Segment Reporting Information [Line Items]
Total costs and operating expenses	4,698	5,209	10,271	10,644
Depreciation and amortization	(427)	(265)	(802)	(503)
Product Sales [Member]
Segment Reporting Information [Line Items]
Total revenues	6,249	3,723	14,236	9,886
Product Sales [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	6,249	3,723	14,236	9,886
Product Sales [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Product Sales [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	6,249	3,723	14,236	9,886
Product Sales [Member] \| Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	6,249	3,723	14,236	9,886
Product Sales [Member] \| Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Research and Development Revenue [Member]
Segment Reporting Information [Line Items]
Total revenues	6,070	9,815	13,665	17,694
Research and Development Revenue [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	4,340	7,442	6,440	12,008
Research and Development Revenue [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	1,730	2,373	7,225	5,686
Research and Development Revenue [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	6,070	9,815	13,665	17,694
Research and Development Revenue [Member] \| Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	4,340	7,442	6,440	12,008
Research and Development Revenue [Member] \| Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	$ 1,730	$ 2,373	$ 7,225	$ 5,686

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

+ Details

Name:	us-gaap_Depreciation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=cdxs_CoreSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=cdxs_BiotherapeuticSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdxs_ProductSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=cdxs_ResearchandDevelopmentRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: